{"id":787594,"date":"2023-10-02T21:57:59","date_gmt":"2023-10-03T01:57:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-publishes-preclinical-data-in-circulation-highlighting-the-clinical-potential-of-cellular-reprogramming-for-cardiac-regeneration\/"},"modified":"2023-10-02T21:57:59","modified_gmt":"2023-10-03T01:57:59","slug":"tenaya-therapeutics-publishes-preclinical-data-in-circulation-highlighting-the-clinical-potential-of-cellular-reprogramming-for-cardiac-regeneration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tenaya-therapeutics-publishes-preclinical-data-in-circulation-highlighting-the-clinical-potential-of-cellular-reprogramming-for-cardiac-regeneration\/","title":{"rendered":"Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration"},"content":{"rendered":"

\nNovel AAV-Based Approach Regenerated Myocardial Cells and Demonstrated Durable Benefit to Heart Function in Rodent Model of Chronic Cardiac Ischemic Injury
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research in the October 3, 2023 issue of the American Heart Association\u2019s (AHA) journal, Circulation<\/em><\/a>. <\/em>The article, titled \u201cImproved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus<\/em><\/a>,\u201d details Tenaya\u2019s initial success in cardiac cellular regeneration utilizing a single adeno-associated viral (AAV) vector to deliver specific combinations of genes to reprogram cells in the heart following ischemic injury.<\/p>\n

\u201cIn an effort to restore contraction to a heart weakened by myocardial infarction, we\u2019ve developed an elegant approach to reprogram select cardiac cells that combines specific genes and regulatory elements into a single adeno-associated vector. Using this approach in a model of chronic ischemic injury we successfully achieved \u2013 for the first time \u2013 dose-dependent and durable improvements in heart function through cardiac regeneration,\u201d said Tim Hoey, Ph.D., Chief Scientific Officer of Tenaya. \u201cSignificant molecular engineering challenges needed to be overcome to make cardiac cellular regeneration feasible for therapeutic development and this work represents a major step forward in advancing the potential application of our cellular reprogramming approach in a clinical setting.\u201d<\/p>\n

An estimated four million people in the U.S. are living with heart failure associated with a prior heart attack, or myocardial infarction (MI). When an MI occurs, cardiomyocytes (CMs), the heart cells responsible for contraction, are lost, while cardiac fibroblasts (CFs), the heart cells that form connective tissue, multiply and contribute to the formation of scar tissue and fibrosis. The loss of CMs following MI permanently impairs heart contraction, leading to heart failure and potentially fatal arrhythmias, and is estimated to result in the death of approximately 5% to 10% of heart attack survivors within the first year. There are currently no approved treatments that address the underlying loss of heart tissue.<\/p>\n

Tenaya researchers achieved several breakthroughs in their effort to create a cellular reprogramming product candidate with potential clinical and commercial viability:<\/p>\n